TP53 and metabolic dysfunction-associated steatohepatitis: Interventions targeting the P53‐MDM2 interaction, such as MDM2 inhibitors, show potential in mitigating liver damage in preclinical models.[17] Understanding the P53‐MDM2 relationship provides insights into therapeutic strategies for MASH and highlights its broader implications in metabolic diseases.